AIM
AIM ImmunoTech Inc
Halal Rating :
Last Price
$0.21
Last updated:
Market Cap
-
7D Change
3.32%
1 Year Change
-49.41%
Company Overview
Industries
Exchange
Next Earnings Date
AIM ImmunoTech Inc is a biopharmaceutical company focused on the research and development of therapeutics for immune disorders, viral diseases, and multiple types of cancer. Their lead drug candidate is Ampligen (rintatolimod), which is being developed for treating conditions including Chronic Fatigue Syndrome (CFS), COVID-19, and various cancers.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $35000.0 | $4.73m | - | $202000.0 | 0.00% | 4.27% |
| June 30, 2024 | $50000.0 | $3.92m | - | $179000.0 | 0.00% | 4.56% |
| March 31, 2024 | $40000.0 | $5.85m | - | $72000.0 | 0.00% | 1.23% |
Company Impact
Help us evaluate AIM ImmunoTech Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.